
Message from the CEO
We will realize “TOP I 2030,” our growth strategy for 2030, with the aim of becoming a top innovator in the healthcare industry
There are many diseases in the world for which there is still no effective treatment. There are also many patients in the world who are waiting for treatment. Chugai’s mission is to continue addressing these unmet medical needs, driven by our strong desire to deliver the therapeutics that patients are waiting for and to contribute to their happiness.
We aim to create new value by addressing societal challenges through our business activities and to grow together with our diverse stakeholders. Based on this idea, we have adopted the idea of creating shared value with society as our basic management policy, and the greatest key to achieving this lies in our focus on innovation. We aim to make advanced and sustainable patient-centered medical care a reality through innovations that only Chugai can create.
Chugai, in collaboration with Roche, is deeply committed to the creation of innovative drugs and aims to become a top innovator in the global healthcare industry. We have formulated a vision of becoming a top innovator by 2030 and the growth strategy “TOP I 2030” to achieve it, with the entire company working together as one to do so.
The driving force behind executing these strategies is none other than our employees. I believe that the source of innovation is, after all, people. It is people who create and develop innovative drugs, and who transform all business processes within the company. We will further enhance the organizational culture that fosters innovation, creating a company where employees with diverse attributes and backgrounds can thrive, grow, and work with vitality. We aim to build a workplace where every individual can proactively design their own careers and take on challenges in realizing their goals.
We are dedicated to pursuing innovation in order to become a top innovator in the global healthcare industry.
Representative Director, President & CEO

As of March 6, 2025